# Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

> **NCT02785913** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 31 (actual)

## Conditions studied

- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Taselisib

## Key facts

- **NCT ID:** NCT02785913
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-02
- **Final completion:** 2019-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02785913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02785913, "Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02785913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*